Platelet P2Y 12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model | Zendy

Mark R. Thomas | Zendy; Samuel Outteridge | Zendy; Ramzi Ajjan | Zendy; Fladia Phoenix | Zendy; Gurpreet K. Sangha | Zendy; Rachael E. Faulkner | Zendy; Rosemary Ecob | Zendy; Heather M. Judge | Zendy; Haroon Khan | Zendy; Laura West | Zendy; David H. Dockrell | Zendy; Ian Sabroe | Zendy; Robert F. Storey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Platelet P2Y ₁₂ Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model

Author(s) -

Mark R. Thomas,

Samuel Outteridge,

Ramzi Ajjan,

Fladia Phoenix,

Gurpreet K. Sangha,

Rachael E. Faulkner,

Rosemary Ecob,

Heather M. Judge,

Haroon Khan,

Laura West,

David H. Dockrell,

Ian Sabroe,

Robert F. Storey

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306528

Subject(s) - inflammation , platelet , systemic inflammation , medicine , thrombosis , cardiology

Clinical studies suggest that platelet P2Y12 inhibitors reduce mortality from sepsis, although the underlying mechanisms have not been clearly defined in vivo. We hypothesized that P2Y12 inhibitors may improve survival from sepsis by suppressing systemic inflammation and its prothrombotic effects. We therefore determined whether clopidogrel and the novel, more potent P2Y12 inhibitor, ticagrelor, modify these responses in an experimental human model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research